Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Key transaction details include:
- Transaction Date: February 16, 2009
- Share Price: £12.34 per Ordinary share; $35.50 per Ordinary Share ADR
- Event: Notional re-investment of the dividend to be paid on April 9, 2009
Material Changes
The filing reports an increase in notional interests in Ordinary shares and ADRs for various executives. No material changes to the company's financial position or operations are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Investor Verification Checklist
- Verify the vesting schedule and conditions for the Performance Share Plan mentioned.
- Confirm the actual dividend payment date and amount scheduled for April 9, 2009.
- Review the full list of participants and their specific notional share increases for compliance with Disclosure and Transparency Rules 3.1.4R(1)(a).